"Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents and adults: A systematic review and network meta-analysis": Reply
| dc.contributor.author | Hollis, Chris P. | |
| dc.date.accessioned | 2018-12-21T09:49:50Z | |
| dc.date.available | 2018-12-21T09:49:50Z | |
| dc.date.issued | 2018 | |
| dc.identifier.citation | Cipriani, A., Adamo, N., Del Giovane, C., Coghill, D., Banaschewski, T., Hollis, C. P., Zuddas, A., Simonoff, E. & Cortese, S. (2018). "Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents and adults: A systematic review and network meta-analysis": Reply. The Lancet Psychiatry, 5 (11), pp.871-873. | en |
| dc.identifier.other | 10.1016/S2215-0366(18)30396-1 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12904/7724 | |
| dc.description.abstract | Replies to comments made by Erlend G. Faltinsen et al (see record 2018-55610-010), Shuai Wang and Yi Zheng (see record 2018-55610-011), and John B. Warren (see record 2018-55610-012) on the authors' original article (see record 2018-43122-019), which was a meta analysis of the comparative efficacy and tolerability of oral medications for ADHD in children, adolescents, and adults. Andrea Cipriani et al agree with Faltinsen and colleagues that standardized mean differences can be difficult to translate into clinical practice. They also agree with Wang and Zheng that systematic reviews should be as comprehensive as possible, and with Warren that it is important to consider reliable information about safety and harms when choosing a pharmacological treatment for ADHD. (PsycINFO Database Record (c) 2018 APA, all rights reserved) | |
| dc.description.uri | https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(18)30396-1/fulltext#%20 | en |
| dc.subject | Attention deficit disorder with hyperactivity | en |
| dc.subject | Outcome assessment (Health care) | en |
| dc.subject | Drug therapy | en |
| dc.title | "Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents and adults: A systematic review and network meta-analysis": Reply | en |
| dc.type | Correspondence | |
| html.description.abstract | Replies to comments made by Erlend G. Faltinsen et al (see record 2018-55610-010), Shuai Wang and Yi Zheng (see record 2018-55610-011), and John B. Warren (see record 2018-55610-012) on the authors' original article (see record 2018-43122-019), which was a meta analysis of the comparative efficacy and tolerability of oral medications for ADHD in children, adolescents, and adults. Andrea Cipriani et al agree with Faltinsen and colleagues that standardized mean differences can be difficult to translate into clinical practice. They also agree with Wang and Zheng that systematic reviews should be as comprehensive as possible, and with Warren that it is important to consider reliable information about safety and harms when choosing a pharmacological treatment for ADHD. (PsycINFO Database Record (c) 2018 APA, all rights reserved) |